JP2023502941A - ロフェコキシブの新規剤形および関連する方法 - Google Patents

ロフェコキシブの新規剤形および関連する方法 Download PDF

Info

Publication number
JP2023502941A
JP2023502941A JP2022528029A JP2022528029A JP2023502941A JP 2023502941 A JP2023502941 A JP 2023502941A JP 2022528029 A JP2022528029 A JP 2022528029A JP 2022528029 A JP2022528029 A JP 2022528029A JP 2023502941 A JP2023502941 A JP 2023502941A
Authority
JP
Japan
Prior art keywords
formulation
rofecoxib
achieves
mean
plasma concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022528029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502941A5 (enExample
Inventor
シッピー，ブラッドフォード，シー．
スクヴィエルチンスキ，レイモンド，ディー．
ヘルム，トラヴィス，イー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tremeau Pharmaceuticals Inc
Original Assignee
Tremeau Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tremeau Pharmaceuticals Inc filed Critical Tremeau Pharmaceuticals Inc
Publication of JP2023502941A publication Critical patent/JP2023502941A/ja
Publication of JP2023502941A5 publication Critical patent/JP2023502941A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022528029A 2019-11-13 2020-11-12 ロフェコキシブの新規剤形および関連する方法 Pending JP2023502941A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962934898P 2019-11-13 2019-11-13
US62/934,898 2019-11-13
US202063018136P 2020-04-30 2020-04-30
US63/018,136 2020-04-30
US16/867,514 US10945992B1 (en) 2019-11-13 2020-05-05 Dosage forms of rofecoxib and related methods
US16/867,514 2020-05-05
PCT/US2020/060152 WO2021097038A1 (en) 2019-11-13 2020-11-12 Novel dosage forms of rofecoxib and related methods

Publications (2)

Publication Number Publication Date
JP2023502941A true JP2023502941A (ja) 2023-01-26
JP2023502941A5 JP2023502941A5 (enExample) 2023-11-21

Family

ID=74870322

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022528029A Pending JP2023502941A (ja) 2019-11-13 2020-11-12 ロフェコキシブの新規剤形および関連する方法

Country Status (9)

Country Link
US (5) US10945992B1 (enExample)
EP (1) EP4058012A1 (enExample)
JP (1) JP2023502941A (enExample)
KR (1) KR20220123224A (enExample)
CN (1) CN115605197A (enExample)
CA (1) CA3155900A1 (enExample)
MX (1) MX2022005813A (enExample)
TW (1) TW202128144A (enExample)
WO (1) WO2021097038A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7291220B2 (ja) 2018-11-21 2023-06-14 トレモ― ファーマシューティカルズ，インコーポレーテッド ロフェコキシブの精製形態、製造方法および使用
US20200323813A1 (en) * 2019-04-09 2020-10-15 Tremeau Pharmaceuticals, Inc. Treatment of viral hemorrhagic fevers with cox-2 selective non-steroidal anti-inflammatory drugs
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof
WO2023059698A1 (en) * 2021-10-06 2023-04-13 Tremeau Pharmaceuticals, Inc. Methods and compositions for treating von willebrand's migraine disorder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040186155A1 (en) * 2003-01-30 2004-09-23 Dayno Jeffrey Marc Combination therapy for the treatment or prevention of migraine
US20070099926A1 (en) * 2003-07-02 2007-05-03 Rodger Ian W Combination therapy for treating chronic inflammatory diseases

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21647A (en) 1858-10-05 Construction of animal-traps
US21042A (en) 1858-07-27 yerby
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
MY119407A (en) 1993-06-24 2005-05-31 Merck Frosst Canada Inc 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5h)-furanone as a cox-2 inhibitor.
CA2180651A1 (en) 1994-01-10 1995-07-13 Yves Ducharme Phenyl heterocycles as cox-2 inhibitors
US5585504A (en) 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
US5849943A (en) 1994-10-27 1998-12-15 Merck Frosst Canada, Inc. Stilbene derivatives useful as cyclooxygenase-2 inhibitors
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
BR9709097A (pt) 1996-05-17 1999-08-03 Merck & Co Inc Composição farmacêutica para o tratamento de doenças mediadas por ciclooxigenase processo para tratar uma doença inflamatória suscetível de tratamento com um agente antinflamatório n o esteróide uso e forma oral de dose unitária
GB9615867D0 (en) 1996-07-03 1996-09-11 Merck & Co Inc Process of preparing phenyl heterocycles useful as cox-2 inhibitors
CN1638739A (zh) 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
JP4659190B2 (ja) 2000-08-31 2011-03-30 アンリツ株式会社 波形測定装置
ES2214129B1 (es) 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 3-fenilfuran-2-onas.
AU2003263582A1 (en) 2003-08-14 2005-03-07 Shasun Chemicals And Drugs Limited Process for the manufacture of rofecoxib
TR200301552A1 (tr) 2003-09-18 2005-10-21 Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. Rofekoksib' in yeni oral farmakolojik formülasyonları.
WO2015066302A2 (en) * 2013-10-30 2015-05-07 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions, methods of use, and methods of treatment
CN104173359B (zh) * 2014-09-05 2017-05-03 罗国安 一种降低罗非考昔副作用的消炎镇痛复方药物及其应用
WO2016089893A1 (en) * 2014-12-01 2016-06-09 Achelios Therapeutics Inc. Methods and compositions for treating migraine and conditions associated with pain
WO2019193417A1 (en) 2018-04-05 2019-10-10 Kossen Co., Ltd. Composition and method of reducing joint pain associated with hemarthrosis
JP7291220B2 (ja) * 2018-11-21 2023-06-14 トレモ― ファーマシューティカルズ，インコーポレーテッド ロフェコキシブの精製形態、製造方法および使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040186155A1 (en) * 2003-01-30 2004-09-23 Dayno Jeffrey Marc Combination therapy for the treatment or prevention of migraine
US20070099926A1 (en) * 2003-07-02 2007-05-03 Rodger Ian W Combination therapy for treating chronic inflammatory diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 55, JPN6024044307, 2003, pages 859 - 894, ISSN: 0005581833 *
STARTUP SEEKING TO RESURRECT VIOXX, ARTHRITIS DRUG PULLED FROM MARKET, JPN6024044306, 21 November 2017 (2017-11-21), ISSN: 0005581834 *

Also Published As

Publication number Publication date
US20220409575A1 (en) 2022-12-29
MX2022005813A (es) 2022-08-16
EP4058012A1 (en) 2022-09-21
WO2021097038A1 (en) 2021-05-20
TW202128144A (zh) 2021-08-01
US20210137878A1 (en) 2021-05-13
CA3155900A1 (en) 2021-05-20
US10945992B1 (en) 2021-03-16
KR20220123224A (ko) 2022-09-06
US20210169845A1 (en) 2021-06-10
CN115605197A (zh) 2023-01-13
US20220047542A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
JP2023502941A (ja) ロフェコキシブの新規剤形および関連する方法
US10682317B2 (en) Ketogenic diet compatible fenfluramine formulation
JP7661315B2 (ja) 高フェニルアラニン血症の治療方法
JP7481402B2 (ja) 皮膚疾患の処置のための併用療法
US20230263786A1 (en) Modulation of drug-drug interactions of vadadustat
TWI850283B (zh) 用於治療糜爛性手部骨關節炎的孟魯司特
US20210137903A1 (en) Anti-androgens for the treatment of prostrate cancer
ULC Aldosterone Antagonist
RU2778848C2 (ru) Состав фенфлурамина, совместимый с кетогенной диетой
TWI243671B (en) Compositions for treating allergic and inflammatory conditions with cough
KR20250024807A (ko) 플로로글루시놀 제제 및 사용 방법
ADVIL et al. CHILDREN’S ADVIL® CHEWABLE TABLETS
WO2025110992A1 (en) Method of administering belumosudil for patient subpopulations with hepatic impairment
MOTRIN Children’s MOTRIN® Suspension
Khatib The most commonly used drugs at the primary health care level in Palestine
CAPLET APO-IBUPROFEN CAPLET
ES PENDO-IBUPROFEN
HK1151726A1 (en) Reduction of dizziness, a side effect associated with pirfenidone therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250425